The UK government said the vaccine would be sold across the UK from next week. In the near future, final recommendations will be issued for priority groups receiving vaccination, including residents of homes for the aged, health and care workers, the elderly and clinically vulnerable groups.
Previously, Pfizer and biontech have signed a contract with the UK government to provide a total of 40 million doses of vaccine to the UK in 2020 and 2021.
According to the daily economic news, biontech and Pfizer have submitted an application for conditional marketing permission of the new crown vaccine candidate to the European drug administration. The European drug administration plans to express its opinions on the new crown vaccine on December 29. It is reported that the U.S. Food and Drug Administrations authorization for the use of the vaccine will also be announced in December.
US media: Pfizers first batch of vaccine delivered on 15th
According to an operation warp speed (ows) document obtained by CNN on December 2, Pfizers first batch of new crown vaccine will be delivered on December 15, while Modernas new crown vaccine is expected to be delivered on December 22.
Operation curvature speed is a program launched by the U.S. government in April to shorten the time required for the development of a new crown vaccine and deliver 300 million doses of vaccine by January 2021. According to HHS official website, curvature speed action list involves Johnson & Johnson, AstraZeneca, Modena, Sanofi, GlaxoSmithKline and Novavax.
The novel coronavirus pneumonia vaccine is a new mRNA crown vaccine. Pfizer vaccine is a BNT162b2 with BioNTech company in Germany. The efficiency is more than 90%. The effectiveness of the new mRNA-1273 vaccine is 94.1%, and the effective rate of severe new crown pneumonia is 100%.
When the research system is similar and the results of the three periods of data are similar, the rest is to race against time to see who will be listed first and seize the market. Affected by the news, Pfizer pharmaceutical 2 U.S. stock trading time rose nearly 3%.
A shares, H shares of biological vaccine concept stocks have fallen
600 thousand new cases of novel coronavirus pneumonia on a single day
180000 new cases in the United States
Novel coronavirus pneumonia confirmed in the world in December 1st, 602 thousand cases all day long, and 96 thousand cases increased from the previous day, according to the statistics of Hopki University. Among them, novel coronavirus pneumonia confirmed in 180 thousand cases in the United States, an increase of 22 thousand cases over the previous day.
Up to now, there have been 63.88 million confirmed cases, 1.48 million deaths and 191 countries and regions.
Scott Gottlieb, former director of the U.S. Food and Drug Administration (FDA), said that by the end of 2020, nearly one-third of US residents (about 100 million people) would eventually be infected with the new coronavirus.
In the past November, it can be said that it was the worst month of the epidemic in the United States. The number of infection cases increased by an alarming rate, and a number of data set new records. According to CCTV news statistics:
The new cases in November accounted for one third of the total cases
The number of inpatients doubled in November
In addition, 29 states in the United States have positive rates of more than 10%.
The World Health Organization has previously said that a positive rate of more than 5% would be worrying because it shows that there are still a large number of cases in the population that have not yet been detected.
Philippe Cassegrain is also known as the father of dumplings.
Longchamp is one of the few French luxury brands still owned and controlled by family members. Because of the image of equestrian and jockey in the brand, it is often called little Hermes.
Philippe Cassegrain is the second generation descendant of Longchamp brand and has worked for the brand for 60 years. In 1993, he designed the famous nylon bag Le pliage, which has become one of the best-selling handbags in the world and has been enduring for a long time.
Longchamp is now in the hands of the third generation of the Cassegrain family. Philippe Cassegrains eldest son, Jean Cassegrain, is CEO, daughter Sophie delafontaine is artistic director, and his youngest son Olivier Cassegrain runs the brands American boutique.
When can China be vaccinated?
Different from the style of overseas vaccine data published for four consecutive weeks, Chinas vaccine research and development and data release appear calm and low-key.
At present, five new coronal vaccines have entered the third phase of clinical trials in China, including Beijing Institute of biological products of Sinopharm group, Wuhan Institute of biological products of Sinopharm group, Beijing Kexing Zhongwei Biological Technology Co., Ltd., kangxinuo biological Co., Ltd., Institute of bioengineering of military medical research, Academy of Military Sciences, and Anhui zhifeilong KOMA biological Co., Ltd Pharmaceutical Co., Ltd.
(photo from finance and economics
Sinopharm, which is responsible for the development of the two vaccines, did not comment on the news.
According to Caijing, kangxinuo biological Co., Ltd. has no preliminary conclusion of phase III clinical trial of its new crown vaccine. Zhifei biological said that on November 18, the companys new crown vaccine in Xiangtan County, Xiangtan City, Hunan Province began the third phase of domestic clinical trials; in late November, the third phase of clinical trials began in Uzbekistan, Indonesia, Pakistan, Ecuador will also be carried out. The companys new crown vaccine is jointly developed with the Institute of Microbiology, Chinese Academy of Sciences. However, as of December 1, there was no sign of any new coronal vaccine on the list of accepted and under trial vaccines in the drug evaluation center (CDE) of the State Food and drug administration. CDE is responsible for the review and approval of Chinese drugs and vaccines. According to the CDE guidelines, if the new crown vaccine has sufficient protective effect and acceptable safety, it is qualified to be approved for marketing. However, even if the protective effect of the vaccine in the interim analysis is good, the phase III clinical trials still need to be completed after the conditional approval. Source: Zhong Qiming, editor in charge of China fund daily_ NF5619
CDE is responsible for the review and approval of Chinese drugs and vaccines. According to the CDE guidelines, if the new crown vaccine has sufficient protective effect and acceptable safety, it is qualified to be approved for marketing. However, even if the protective effect of the vaccine in the interim analysis is good, the phase III clinical trials still need to be completed after the conditional approval.